NCT06625515 2026-02-24First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersAccent TherapeuticsPhase 1 Terminated17 enrolled
NCT04106167 2023-09-21Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyFate TherapeuticsTerminated20 enrolled